100 related articles for article (PubMed ID: 15181135)
1. PET for the evaluation of pleural thickening observed on CT.
Kramer H; Pieterman RM; Slebos DJ; Timens W; Vaalburg W; Koëter GH; Groen HJ
J Nucl Med; 2004 Jun; 45(6):995-8. PubMed ID: 15181135
[TBL] [Abstract][Full Text] [Related]
2. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
Gerbaudo VH; Sugarbaker DJ; Britz-Cunningham S; Di Carli MF; Mauceri C; Treves ST
J Nucl Med; 2002 Sep; 43(9):1144-9. PubMed ID: 12215551
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
[TBL] [Abstract][Full Text] [Related]
4. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
Carretta A; Landoni C; Melloni G; Ceresoli GL; Compierchio A; Fazio F; Zannini P
Eur J Cardiothorac Surg; 2000 Apr; 17(4):377-83. PubMed ID: 10773558
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
Duysinx B; Nguyen D; Louis R; Cataldo D; Belhocine T; Bartsch P; Bury T
Chest; 2004 Feb; 125(2):489-93. PubMed ID: 14769729
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
7. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
Orki A; Akin O; Tasci AE; Ciftci H; Urek S; Falay O; Kutlu CA
Thorac Cardiovasc Surg; 2009 Jun; 57(4):217-21. PubMed ID: 19670115
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
Schneider DB; Clary-Macy C; Challa S; Sasse KC; Merrick SH; Hawkins R; Caputo G; Jablons D
J Thorac Cardiovasc Surg; 2000 Jul; 120(1):128-33. PubMed ID: 10884665
[TBL] [Abstract][Full Text] [Related]
9. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
10. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
[TBL] [Abstract][Full Text] [Related]
12. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.
Bar-Shalom R; Yefremov N; Guralnik L; Gaitini D; Frenkel A; Kuten A; Altman H; Keidar Z; Israel O
J Nucl Med; 2003 Aug; 44(8):1200-9. PubMed ID: 12902408
[TBL] [Abstract][Full Text] [Related]
14. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
Ng DC; Hain SF; O'Doherty MJ; Dussek J
J Nucl Med; 2000 Aug; 41(8):1443-4. PubMed ID: 10945542
[No Abstract] [Full Text] [Related]
17. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
18. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]